US Patent 9,700,592: Bremelanotide Patent Scope, Validity, Exclusivity and Generic Entry Risk

US Patent No. 9,700,592 protects specific subcutaneous bremelanotide treatment protocols for female sexual dysfunction, particularly hypoactive sexual desire disorder. Its core limitation is not bremelanotide itself. The patent covers administering approximately 1.25 mg to 1.75 mg of bremelanotide by subcutaneous injection to a diagnosed female patient anticipating sexual activity, with reduced or minimized adverse effects compared with intranasal administration.

The strongest commercial embodiment is a 1.75 mg subcutaneous dose, corresponding to the Vyleesi product approved by the U.S. Food and Drug Administration. The patent is a method-of-use patent with pharmacokinetic and tolerability limitations. It does not independently prevent all manufacture, sale, or use of bremelanotide outside the claimed treatment conditions.

What patent is US 9,700,592 and who owns it?

US 9,700,592 is titled "Methods of Treating Female Sexual Dysfunction." The patent was assigned to Palatin Technologies, Inc., the developer of bremelanotide. It issued on July 25, 2017, from U.S. patent application No. 14/219,674 and has a stated expiration date of March 18, 2031, before any applicable patent-term adjustment or pediatric extension.[1]

Item	Details
U.S. patent	9,700,592
Title	Methods of Treating Female Sexual Dysfunction
Patent type	Method-of-treatment, method-of-use
Active ingredient	Bremelanotide or a pharmaceutically acceptable salt
Administration route	Subcutaneous injection
Claimed dose	About 1.25 mg to 1.75 mg net peptide weight
Primary indication	Female sexual dysfunction
Specific disease in dependent claims	Hypoactive sexual desire disorder
Key comparator	Intranasal bremelanotide
Issue date	July 25, 2017
Stated expiration	March 18, 2031
Original developer	Palatin Technologies, Inc.

The patent is directed to clinical use rather than a new molecular entity. Its commercial relevance comes from the alignment between the claims and the approved Vyleesi dosing regimen.

What do the independent claims of US 9,700,592 cover?

Claims 1 and 9 are the principal independent claims.

Claim 1 requires all of the following:

A female human patient.
A diagnosis of female sexual dysfunction.
Anticipation of sexual activity.
Subcutaneous administration.
A composition containing about 1.25 mg to 1.75 mg net peptide weight of bremelanotide or a pharmaceutically acceptable salt.
Treatment of female sexual dysfunction.
Reduced or minimized side effects compared with intranasal administration of an equivalent dosage.

Claim 9 is narrower in dose but omits the express intranasal comparison. It requires:

a female patient diagnosed with female sexual dysfunction;
anticipated sexual activity;
subcutaneous injection;
approximately 1.75 mg net peptide weight;
treatment of the condition; and
reduction of undesirable side effects.

Claim 9 is commercially important because it maps closely to the approved 1.75 mg Vyleesi injection while avoiding some of claim 1's explicit comparator language.

How does claim 1 differ from claim 9?

Issue	Claim 1	Claim 9
Dose	About 1.25 to 1.75 mg	About 1.75 mg
Route	Subcutaneous	Subcutaneous
Patient	Diagnosed female patient anticipating sexual activity	Same
Side-effect limitation	Compared with equivalent intranasal dose	Reduced undesirable side effects
Intranasal comparator	Expressly required	Not expressly required
Potential infringement scope	Broader dose range but more comparator-dependent	Narrower dose, potentially easier factual proof

Claim 1 may be more vulnerable to disputes over whether the accused product or clinical use satisfies the intranasal comparison. Claim 9 may be more practical in litigation involving a 1.75 mg subcutaneous product because it focuses on the dose, route, patient population and clinical result.

What formulations and doses are protected by US 9,700,592?

The patent protects use of bremelanotide compositions containing approximately 1.25 mg to 1.75 mg of net peptide weight. It does not require a particular excipient system in the claims provided. The claim is therefore directed primarily to dose and administration method rather than to a detailed formulation composition.

"Net peptide weight" is significant. The dose is measured by the amount of bremelanotide peptide, not necessarily the total mass of a salt, counterion, excipient, cartridge, vial or finished drug product. A salt formulation may fall within the claims if it delivers the specified amount of bremelanotide peptide.

The most commercially relevant dose is 1.75 mg. FDA labeling for Vyleesi instructs patients to inject 1.75 mg subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity. Use is limited to one dose within 24 hours and no more than eight doses per month.[2]

What does the patent not expressly require?

The claims provided do not expressly require:

a particular syringe or autoinjector;
a particular excipient;
a particular pH;
a specific concentration;
a particular container closure;
a specific manufacturing process;
a particular brand;
a particular peptide sequence beyond bremelanotide;
a particular injection site; or
a specific commercial formulation such as Vyleesi.

A competing product could therefore face method-of-use risk even if it uses a different device or excipient system.

How do the pharmacokinetic limitations affect patent scope?

Claims 3 through 7 add pharmacokinetic limitations that narrow the protected methods.

Claim 3 requires the intranasal dose to produce a similar peak plasma concentration within 60 minutes compared with a 1.75 mg subcutaneous dose. Claim 4 defines the relevant mean peak plasma concentration as approximately 60 to 120 ng/mL.

Claims 6 and 12 require a coefficient of variation below 30% for peak plasma concentration within 60 minutes after subcutaneous injection. Claims 7 and 13 require lower variability for subcutaneous administration than for intranasal administration. Claim 15 specifies that intranasal variability is greater than 30%.

These limitations create several enforcement issues:

Peak plasma concentration must be measured using a defined pharmacokinetic protocol.
"Similar" concentration may require expert testimony regarding acceptable statistical or clinical boundaries.
The claims concern population-level measurements, not necessarily every individual patient.
The relevant measurement window is limited to 60 minutes.
A generic sponsor may argue that its data do not establish the claimed coefficient of variation.
The patent owner may argue that the accused label directs use that inherently produces the claimed pharmacokinetic profile.

The pharmacokinetic claims can strengthen validity by tying the method to measurable clinical performance. They can also complicate infringement proof because the patent does not merely require administration of a dose. It requires a specified pharmacokinetic outcome or comparative variability for several dependent claims.

What side effects are covered by the patent?

Claims 2 and 11 identify the following side effects:

nausea;
flushing;
headache;
changes in systolic blood pressure;
changes in diastolic blood pressure;
changes in heart rate;
vomiting; and
hypertension.

The FDA label identifies nausea, flushing, injection-site reactions, headache and vomiting among the principal adverse reactions associated with Vyleesi. Nausea was reported in approximately 40% of patients in clinical studies, and the label warns about transient increases in blood pressure and reductions in heart rate.[2]

The patent does not require elimination of side effects. It uses "reducing or minimizing" or "reducing undesirable side effects." That language supports an argument that a relative reduction is sufficient. The scope remains dependent on claim construction and proof of the claimed clinical result.

When does US 9,700,592 lose exclusivity?

The patent's stated expiration date is March 18, 2031.[1] The effective exclusivity date may be affected by:

patent-term adjustment;
patent-term extension;
pediatric exclusivity;
terminal disclaimers in related patents;
Orange Book listing status; and
any litigation settlement permitting an earlier launch.

The patent does not appear to receive the five-year patent-term extension available to a new chemical entity because bremelanotide was previously investigated and the patent claims a treatment method rather than the active ingredient as a new molecular entity.

Vyleesi received FDA approval on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder in premenopausal women.[3] The approval was supported by FDA regulatory exclusivity associated with the new indication and product approval. Regulatory exclusivity and patent exclusivity are separate rights. FDA approval does not extend the patent expiration date.

What is the Orange Book status of bremelanotide and Vyleesi?

Vyleesi is approved under NDA 210557. The FDA Orange Book is the controlling source for current patent listings and regulatory exclusivity information.[4]

US 9,700,592 is commercially relevant as a method-of-use patent because its claims track the approved subcutaneous 1.75 mg treatment. A listed method-of-use patent can require an ANDA applicant to submit a Paragraph IV certification if the applicant seeks approval before patent expiration and does not accept a use carve-out.

The practical Orange Book question is whether an ANDA applicant can omit the patented use from its proposed labeling. If the generic label excludes the patented female sexual dysfunction indication and does not encourage the claimed use, a Section viii statement may be available. If the FDA-approved labeling necessarily includes the indication, or if the proposed labeling directs the patented regimen, a Paragraph IV certification is more likely.

Are there Paragraph IV challenges or patent litigation involving Vyleesi?

A Paragraph IV challenge is the principal litigation pathway for a generic seeking approval before March 18, 2031. The applicant would allege that the patent is invalid, unenforceable or not infringed.

The primary legal issues would likely include:

Infringement

A patent owner would need to establish that the generic's labeling, instructions or induced use satisfies the elements of at least one asserted claim. Claim 9 may be the most direct assertion against a product labeled for 1.75 mg subcutaneous dosing.

Written description and enablement

The claims cover a dose range and clinical outcomes involving reduced side effects and pharmacokinetic variability. A challenger could argue that the specification does not support the full scope of all dose, patient and pharmacokinetic combinations. The patent owner would rely on clinical data and examples showing the relationship between subcutaneous dosing, exposure and tolerability.

Obviousness

Bremelanotide, intranasal administration and subcutaneous administration were known in the development history of the drug. A challenger could argue that moving from intranasal to subcutaneous delivery at a therapeutically effective dose was predictable. The patent owner would counter that the combination of improved tolerability, lower pharmacokinetic variability and clinically useful exposure was unexpected.

Definiteness

Terms such as "about," "similar peak plasma concentration," "reducing," and "minimizing" may be challenged as indefinite. The patent owner would argue that the specification and clinical data provide objective boundaries.

No publicly documented major Paragraph IV trial or settlement involving US 9,700,592 is identified in the sources cited here. The absence of a reported challenge does not eliminate future ANDA risk. The patent remains relevant until expiration or a successful challenge.

How strong is the patent estate for Vyleesi?

The estate is strongest against a generic that:

uses the 1.75 mg subcutaneous dose;
labels the product for female sexual dysfunction or hypoactive sexual desire disorder;
instructs administration before anticipated sexual activity; and
relies on a label substantially similar to Vyleesi.

The estate is weaker against:

a product approved only for a non-patented indication;
a lower or higher dose outside the claimed range;
a product with a genuine Section viii use carve-out;
a product whose labeling does not encourage treatment of female sexual dysfunction; or
a product with clinical data that do not meet the comparative pharmacokinetic limitations.

Risk factor	Assessment
1.75 mg subcutaneous labeled product	High method-of-use risk
1.25-1.75 mg subcutaneous product for the patented indication	High risk
Different device using the same dose and indication	Device change alone likely insufficient
Different excipients	May not avoid method claims
Nonsexual-dysfunction indication	Lower risk if labeling is properly carved out
Intranasal product	Outside the subcutaneous route limitation, although comparator language remains relevant
Product outside the claimed dose range	Potentially lower risk
Biosimilar pathway	Not applicable to bremelanotide, a synthetic peptide drug
ANDA Paragraph IV	Principal early-entry pathway

Which companies are challenging Vyleesi or competing with bremelanotide?

The relevant competitive set includes:

Palatin Technologies, as originator and intellectual-property developer;
AMAG Pharmaceuticals, which commercialized Vyleesi in the United States under license;
Cosette Pharmaceuticals, which acquired Vyleesi commercialization rights from AMAG; and
Addyi, marketed by Sprout Pharmaceuticals, as the principal branded pharmacologic competitor for hypoactive sexual desire disorder.[5]

Addyi contains flibanserin and is administered orally on a daily basis. Vyleesi is administered on demand by subcutaneous injection. The products have different mechanisms, dosing schedules, contraindications and patent profiles.

Product	Active ingredient	Route	Dosing model	Core indication
Vyleesi	Bremelanotide	Subcutaneous injection	On demand before sexual activity	Acquired, generalized HSDD in premenopausal women
Addyi	Flibanserin	Oral	Daily at bedtime	Acquired, generalized HSDD in premenopausal and postmenopausal women under current labeling

The biosimilar framework does not apply. Bremelanotide is a synthetic peptide drug, not a biologic approved through the Public Health Service Act pathway. A competing applicant would generally pursue an ANDA or another drug application pathway, depending on the product's formulation and regulatory characteristics.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Early launch after a successful Paragraph IV case

A generic could launch before March 18, 2031 if it invalidates or avoids the asserted patent and satisfies FDA requirements. This is the highest-impact scenario for Vyleesi revenue.

Negotiated launch

A settlement could establish an agreed launch date before patent expiration. The settlement could include restrictions based on formulation, indication, route, or labeling.

Launch after patent expiration

Absent an earlier settlement or successful challenge, a generic labeled for the patented use would face the clearest path after patent expiration, subject to other listed patents and regulatory requirements.

Because the principal patent covers the approved dose and route, a generic seeking the full Vyleesi indication would have limited practical value from a simple formulation change. A successful design-around would more likely require a different dose, indication, route or label strategy.

What manufacturing and intellectual-property barriers remain?

US 9,700,592 does not claim the manufacturing process in the claims provided. Manufacturing barriers therefore arise mainly from formulation development, peptide synthesis, stability, device compatibility, analytical testing and FDA approval requirements rather than from this patent alone.

A generic developer would need to address:

peptide identity and purity;
salt form and net peptide equivalence;
degradation products;
container and device compatibility;
injection-site tolerability;
pharmacokinetic comparability;
stability over the proposed shelf life; and
labeling that either includes or carves out the patented indication.

Geographic protection is territorial. US 9,700,592 affects U.S. conduct only. Corresponding foreign patents, national-phase applications and expiration dates must be analyzed separately. A U.S. patent expiration does not terminate patent rights in Europe, Japan, Canada or other jurisdictions.

Key Takeaways

US 9,700,592 is a method-of-use patent, not a composition-of-matter patent for bremelanotide.
The core protected regimen is approximately 1.25 mg to 1.75 mg of bremelanotide administered subcutaneously to a diagnosed female patient anticipating sexual activity.
The 1.75 mg claim closely tracks the FDA-approved Vyleesi regimen.
The patent adds tolerability and pharmacokinetic limitations, including reduced side effects, mean peak plasma concentrations and coefficients of variation.
The stated patent expiration date is March 18, 2031.
An ANDA applicant seeking the full Vyleesi indication would face meaningful Paragraph IV and induced-infringement risk.
A Section viii carve-out may reduce risk if the generic label omits the patented female sexual dysfunction use and does not encourage it.
Bremelanotide is not subject to the biosimilar pathway.
The main branded competitive product is Addyi, which has a different active ingredient, route and dosing schedule.
The commercial strength of US 9,700,592 depends more on label overlap and clinical-use evidence than on formulation similarity.

Frequently Asked Questions

Can a generic sell bremelanotide before 2031 for another indication?

Potentially. A generic may reduce infringement risk through a use-specific labeling carve-out, but the proposed label and promotional conduct must not encourage the patented female sexual dysfunction regimen.

Does using a different autoinjector avoid US 9,700,592?

Not necessarily. The claims provided do not require a particular injection device. A different device may still infringe if the dose, route, patient population and treatment use satisfy the claims.

Does the patent cover oral bremelanotide?

No. The independent claims require subcutaneous injection. Oral administration does not satisfy that express route limitation, although other patents or regulatory barriers could apply.

Is a bremelanotide competitor a biosimilar?

No. Bremelanotide is a synthetic peptide drug. A competitor would generally be evaluated under a drug approval pathway rather than the biosimilar pathway.

What is the most important infringement issue for Vyleesi generics?

The key issue is whether the proposed generic label directs or encourages the 1.75 mg subcutaneous treatment of female sexual dysfunction before anticipated sexual activity. That issue may be more important than whether the generic uses the same excipients or injection device.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,700,592: Methods of treating female sexual dysfunction.
U.S. Food and Drug Administration. (2023). Vyleesi (bremelanotide) injection prescribing information. AMAG Pharmaceuticals/Cosette Pharmaceuticals.
U.S. Food and Drug Administration. (2019, June 21). FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Addyi (flibanserin) prescribing information.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013337341	⤷ Start Trial
Brazil	112015009936	⤷ Start Trial
Canada	2890081	⤷ Start Trial
China	104755094	⤷ Start Trial
Denmark	2916856	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,700,592

Which drugs does patent 9,700,592 protect, and when does it expire?

Summary for Patent: 9,700,592